Study of 18F-Fluciclovine PETCT Imaging for Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

What this Trial Is About

Brain metastases occur when cancer spreads to the brain and are a common complication in cancer patients. Researchers are studying a new imaging agent called 18F-fluciclovine to see if it can detect which patients respond to radiation therapy. The study also aims to monitor changes in the treated brain metastases over time using this imaging agent. Participants will receive three 18F-fluciclovine PETCT brain scans before treatment, during treatment, and after treatment. The 18F-fluciclovine, also known as Axumin, is given as an intravenous injection with a maximum undiluted volume of 5 mL, followed by a saline flush. Patients must fast for at least four hours before injection, and PET images will be collected and analyzed to assess treatment response. During the study, participants will undergo PETCT and MRI scans at multiple time points up to one year to evaluate changes in imaging sensitivity and standardized uptake value SUV parameters. Researchers will compare PET and MRI results over time to understand the effects of radiation therapy on brain metastases. Patient safety and treatment response will be closely monitored throughout the study period.

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery